Dupilumab
Treatment for Eczema
Typical Dosage: 600 mg initial, then 300 mg SC every two weeks
Effectiveness
90%
Safety Score
60%
Clinical Trials
108
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
600 mg initial, then 300 mg SC every two weeks
Time to Effect
2-4 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$39,000
Monitoring:$400
Side Effect Mgmt:$100
Total Annual:$39,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$135,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$60,769
Cost per Remission
$158,000
Comparison vs Cyclosporine + Topical Corticosteroids
Cost Difference
+$34,500/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Dupilumab Outcomes
for Eczema
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+65%
Remission Rate
+25%
Common Side Effects
Injection site reactions
+15%
Conjunctivitis
+10%
Oral herpes
+3%
Eosinophilia
+3%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
10 active trials recruiting for Dupilumab in Eczema
DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
NCT06004986RECRUITINGPHASE4
216 participants
INTERVENTIONAL
Amsterdam, Netherlands +1 more
Started: Aug 14, 2023
A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.
NCT07358156RECRUITINGPHASE1
519 participants
INTERVENTIONAL
Berlin, Germany +1 more
Started: Feb 9, 2026
Dupixent and Narrowband UVB for Atopic Dermatitis
NCT05285839RECRUITINGPHASE4
40 participants
INTERVENTIONAL
East Windsor, United States
Started: Apr 19, 2022
A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab
NCT06169527ACTIVE NOT RECRUITING
303 participants
OBSERVATIONAL
Amiens, France +41 more
Started: Nov 28, 2023
Ethnic Differences in Mechanisms of Action of Dupilumab
NCT05268107RECRUITINGPHASE4
30 participants
INTERVENTIONAL
Ann Arbor, United States
Started: Jan 25, 2023
Dupilumab De-escalation in Pediatric Atopic Dermatitis
NCT06116526RECRUITINGPHASE4
30 participants
INTERVENTIONAL
Baltimore, United States
Started: Apr 1, 2024
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
NCT05042258RECRUITINGPHASE4
40 participants
INTERVENTIONAL
Chicago, United States
Started: Aug 12, 2024
Molecular Signatures of Cutaneous Dupilumab Response
NCT05858619RECRUITINGPHASE4
15 participants
INTERVENTIONAL
San Francisco, United States
Started: Feb 1, 2023
Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
NCT06415175ACTIVE NOT RECRUITING
143 participants
OBSERVATIONAL
Santiago de Compostela, Spain +14 more
Started: Nov 14, 2024
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07467564RECRUITING
184 participants
OBSERVATIONAL
Abu Dhabi, United Arab Emirates
Started: Feb 24, 2026
Completed Clinical Trials
7 completed trials for Dupilumab in Eczema
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
NCT03293030COMPLETEDPHASE4
17 participants
INTERVENTIONAL
San Francisco, United States
Started: Oct 22, 2018
The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients
NCT03667014COMPLETEDPHASE4
34 participants
INTERVENTIONAL
San Francisco, United States
Started: Nov 1, 2018
Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids
NCT03861455COMPLETEDPHASE2
94 participants
INTERVENTIONAL
Bordeaux, France +3 more
Started: Jul 15, 2019
Open-label Study of Dupilumab in Patients With Atopic Dermatitis
NCT01949311COMPLETEDPHASE3
2.73K participants
INTERVENTIONAL
Anniston, United States +431 more
Started: Oct 10, 2013
Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China
NCT05680298COMPLETEDPHASE4
34 participants
INTERVENTIONAL
Beijing, China
Started: Feb 22, 2023
A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)
NCT02407756COMPLETEDPHASE2
78 participants
INTERVENTIONAL
Markham, Canada +25 more
Started: Mar 31, 2015
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
NCT04358224COMPLETEDPHASE4
12 participants
INTERVENTIONAL
Cincinnati, United States
Started: Sep 1, 2020
Showing 20 of 116 total trials